A Recent MHRA Recall Shows Why Recall Readiness Matters for Medicines Wholesalers
The MHRA recently announced a precautionary recall of one batch of Sertraline 100mg film-coated tablets after a manufacturing error led to incorrect blister strips being found inside a sealed carton. Healthcare professionals were advised to stop supplying the affected batch and return all remaining stock.
For patients and healthcare professionals, this type of alert is about safety and making sure the right product is supplied.
For medicines wholesale businesses, it is also a reminder of something very practical:
Recall readiness matters.
What Happened and Why It Matters
The recall involved a packaging issue where a pack of Sertraline 100mg tablets contained a blister strip of Citalopram 40mg tablets inside the sealed carton. The MHRA said the error appeared to have happened during secondary packaging at the manufacturing site.
This does not mean every recall creates the same level of risk.
But every recall does require a controlled response.
- A business needs to know:
- Where is the affected stock?
- Has any of it already been supplied?
- Who received it?
- How quickly can supply be stopped?
- Who needs to be contacted?
- What records are needed?
- Who is responsible for each action?
That is where GDP systems become important.
What This Means for Medicines Wholesale Businesses
A recall is not just a message to read and file.
For a medicines wholesale business, it can test the whole quality system.
If the business cannot quickly identify stock, trace supply, stop movement, quarantine affected products and record its actions, the recall process becomes harder to manage.
This can create avoidable risk.
The MHRA’s inspection guidance explains that inspectors may review areas such as stock management, storage areas, returns areas, purchasing and sales functions, transportation arrangements, documents and relevant personnel during inspections.
That matters because recall handling touches many of those same areas.
A weak recall process may reveal wider weaknesses in:
- Stock control
- Traceability
- Supplier communication
- Customer records
- SOPs
- Training
- Escalation
- Responsible Person oversight
- CAPA
- Documentation
Why Responsible Person Oversight Matters
The Responsible Person should have visibility over the quality system and should be able to understand how recall risks are being managed.
That does not mean the RP personally carries out every task.
It means the RP should have confidence that the process is clear, documented and followed.
A good recall process should answer simple questions:
- Who receives alerts?
- Who checks whether stock is affected?
- Who stops supply?
- Who contacts customers?
- Who records the action?
- Who checks completion?
- Who reviews whether the process worked?
If those answers are unclear, the business may not be as ready as it thinks.
What Businesses Should Check Now
This news is a useful reminder for any business involved in medicines wholesale, WDA(H) readiness or GDP compliance.
- You should consider reviewing:
- Your recall SOP
- Your stock traceability process
- Your customer notification process
- Your supplier communication route
- Your quarantine and return process
- Your Responsible Person visibility
- Your deviation and CAPA process
- Your training records
- Your mock recall testing
- Your document control
A recall process should not only exist on paper.
It should work in real life.
How Stag Global Helps
Stag Global does not supply medicines or products.
We support businesses with compliance-led review and readiness support, helping them understand whether their systems, people and controls are strong enough before pressure arrives.
This may include:
- GDP audit and readiness support
- Responsible Person / GDP quality support
- Recall readiness review
- SOP and quality system review
- CAPA and deviation process support
- Compliance route reviews
- WDA(H) application readiness
- Ongoing compliance support
Our role is to help businesses move forward with clarity, control and confidence.
We help clients understand what is working, what may be missing and what needs attention next.
Final Thought
A medicine recall is not only a product issue.
It is a system test.
It tests whether a business can act quickly, trace accurately, communicate clearly and record properly.
For medicines wholesalers, that is not just good practice.
It is part of building a stronger, safer and more defensible GDP compliance position.
Book a confidential consultation with Stag Global to review your compliance position before pressure arrives.
